Susquehanna International Group’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $124K | Sell |
11,242
-2,147
| -16% | -$33.2K | ﹤0.01% | 12192 |
|
|
2025
Q4 | $273K | Sell |
13,389
-203,311
| -94% | -$3.57M | ﹤0.01% | 10172 |
|
|
2025
Q3 | $3.43M | Buy |
216,700
+103,035
| +91% | +$1.52M | 0.01% | 4725 |
|
|
2025
Q2 | $1.52M | Sell |
113,665
-8,184
| -7% | -$110K | ﹤0.01% | 6412 |
|
|
2025
Q1 | $1.24M | Sell |
121,849
-89,460
| -42% | -$1.04M | ﹤0.01% | 6710 |
|
|
2024
Q4 | $3.35M | Buy |
211,309
+202,261
| +2,235% | +$10.5M | 0.01% | 4260 |
|
|
2024
Q3 | $525K | Buy |
9,048
+666
| +8% | +$32.9K | ﹤0.01% | 8350 |
|
|
2024
Q2 | $383K | Sell |
8,382
-7,043
| -46% | -$378K | ﹤0.01% | 8897 |
|
|
2024
Q1 | $1.02M | Sell |
15,425
-107
| -0.7% | -$6.34K | ﹤0.01% | 6867 |
|
|
2023
Q4 | $618K | Buy |
+15,532
| New | +$487K | ﹤0.01% | 8150 |
|
|
2023
Q3 | – | Sell |
-8,770
| Closed | -$352K | – | 12617 |
|
|
2023
Q2 | $352K | Sell |
8,770
-17,783
| -67% | -$780K | ﹤0.01% | 9109 |
|
|
2023
Q1 | $1.13M | Buy |
26,553
+18,546
| +232% | +$937K | ﹤0.01% | 6485 |
|
|
2022
Q4 | $384K | Sell |
8,007
-28,015
| -78% | -$1.31M | ﹤0.01% | 8483 |
|
|
2022
Q3 | $1.35M | Buy |
+36,022
| New | +$1.25M | ﹤0.01% | 5848 |
|
|
2022
Q2 | – | Sell |
-20,045
| Closed | -$1.09M | – | 13601 |
|
|
2022
Q1 | $1.09M | Buy |
20,045
+2,712
| +16% | +$139K | ﹤0.01% | 6885 |
|
|
2021
Q4 | $1.01M | Buy |
17,333
+4,380
| +34% | +$218K | ﹤0.01% | 7255 |
|
|
2021
Q3 | $512K | Buy |
12,953
+4,230
| +48% | +$151K | ﹤0.01% | 9343 |
|
|
2021
Q2 | $370K | Buy |
+8,723
| New | +$473K | ﹤0.01% | 10319 |
|
|
2021
Q1 | – | Sell |
-6,398
| Closed | -$451K | – | 12644 |
|
|
2020
Q4 | $451K | Buy |
+6,398
| New | +$403K | ﹤0.01% | 8508 |
|
Other funds holding KROS
NCM
VCM
O
VPM
MAP